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1. INTRODUCTION 
 
1.1. Pathophysiology of acute pancreatitis 
The spectrum of acute pancreatitis (AP) ranges from a mild edematous disease to a severe 
necrotizing process which is usually accompanied by local or systemic complications. 
Although the exact mechanisms which trigger the inflammatory and necrotizing processes are 
not completely understood, it is generally accepted that autodigestion and an acute 
inflammatory response of the pancreas via the activation of proteases of the pancreas and 
activated leukocytes play important roles in the pathogenesis of AP. This amplified cytokine 
response is one of the most important pathophysiological factors in the development of 
complications, and especially in the progression of a limited local pancreatic inflammation 
into a potentially dangerous systemic inflammatory reaction termed multiple organ 
dysfunction syndrome. The incidence of AP has increased in the past two decades. The 
incidence of first-time attacks in the USA has increased from 33 to 44 per 100,000 adults, and 
at present AP accounts for more than 200,000 hospital admissions per year. AP is a relatively 
common disease in Europe, with a case incidence of 10 to 30 per 100,000 inhabitants. In 80% 
of the cases, the disease is mild, without significant morbidity or mortality. However, in 20% 
of the patients the disease is severe, with a stable frequency of mortality rate of around 25%-
30%. The situation giving rise to AP determines its epidemiology. The most frequent cause is 
biliary stone migration. Although the etiological agents differ considerably, the ultimate 
outcome is relatively independent of the causative factors.  
 
1.2. Scientific background 
 During the past twenty years, much evidence has accumulated which indicaties that 
proinflammatory mediators such as tumor necrosis factor-alpha (TNF-α), certain interleukins 
(IL-1 beta, IL-6, IL-8 and IL-10), prostaglandins, the arachidonic acid metabolism and many 
other biological active mediators play significant roles in the pathogenesis of AP, which can 
range from a mild illness to a lifethreatening condition. These mediators are primarily 
responsible for the distant organ complications (multiorgan failure) in severe AP. 
The beneficial effect of glucocorticoid hormones in the treatment of human AP was originally 
reported by Stephenson et al. in the early 1950s. Since that time, the role of glucocorticoids 
has been investigated in various types of in vivo and in vitro experimental AP models. It has 
been reported to result paradoxically in the release of both anti-inflammatory (glucocorticoid 
hormones) and proinflammatory (macrophage migration inhibitory factor; MIF) mediators. 
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This counter-regulatory mechanism is essential for the provision of appropriate control of the 
ensuing inflammatory cascade. 
The glucocorticoids are known to be involved in the regulation of cytokine production and the 
inflammatory processes. The corticosteroids inhibit the synthesis of TNF-α, IL-1, IL-6 and 
IL-8 and the function of nitric oxide synthase, and reduce complement activation and 
complement-induced leukocyte activation.  
The proinflammatory cytokines activate the hypothalamic-pituitary-adrenal axis, stimulating 
pituitary adrenocorticotropin secretion and the resulting release of endogenous 
glucocorticoids, which are the most important endogenous modulators of inflammatory and 
immune responses. Recent studies have demonstrated the bidirectional communication 
between the neuroendocrine and immune systems, and this special feedback loop balances the 
intensity of the immune response and moderates the morbidity and mortality associated with 
the systemic inflammatory reaction. 
Furthermore, glucocorticoids protect the acinar cells, stabilize the cell membrane and directly 
regulate amylase synthesis. Nevertheless, the effects of glucocorticoids on the clinical or 
experimental forms of AP have remained contradictory. 
Low doses of glucocorticoids induce the secretion of MIF, a potent proinflammatory 
molecule which controls the synthesis of glucocorticoids and the action of inflammatory 
mediators (IL-1, IL-6, IL-8 and TNF). However, this regulatory role of MIF on the anti-
inflammatory/immunosuppressive effects of glucocorticoid hormones has not been fully 
elucidated.  
 
AIMS OF THE STUDY 
 
Our primary goal was to create clinically relevant animal models suitable for investigations of 
the pathophysiology of AP and different treatment options. 
We therefore set out to study the consequences of the administration of the exogenous 
glucocorticoid agonists dexamethasone (DEX), hydrocortisone (HYD) and 
methylprednisolone (MP) and the antagonist RU-38486 (RU) on on the local and systemic 
responses of AP, including the mortality, the severity, the levels of proinflammatory and 
inflammatory mediators, the local histopathological changes, and liver and lung injuries in 
experimental AP. Within this topic we investigated, 
• the effects of glucocorticoid agonist and antagonist hormones on the mortality in AP; 
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• the effects of glucocorticoid agonist and antagonist hormones on the proinflammatory 
and inflammatory mediators in the plasma and in different target organs in AP; 
• the effects of glucocorticoid agonist and antagonist hormones on the changes in 
pancreatitis markers in AP; 
• the characterization of leukocyte infiltration by myeloperoxidase (MPO) in distant 
target organs the liver and lungs in AP; 
• the role of adenosine triphosphate (ATP) level changes in distant target organs the 
liver and lungs in AP; 
• the effects of glucocorticoid agonist and antagonist hormones on MIF level regulation; 
• the role of glucocorticoid hormones in the regulation of the pancreatic nuclear 
transcription factor kappa B (NF-κB) activity; 
• the effects of glucocorticoids on histological changes in the pancreas and distant 
organs the lungs and liver in experimental AP models. 
  
2. MATERIALS AND METHODS 
 
Animals 
Male outbred Wistar rats (weighing 250-280 g) were used in all experiments. 
  
2.1. Experimental protocols 
2.1.1. Study I 
The animals were allocated to one or other of eight groups. In group 1, AP was induced by the 
retrograde administration of 400 mg Na-taurocholate into the pancreatic duct (group AP). In 
groups 2, 3 and 4, the animals were given 4 mg/kg body weight (bw) dexamethasone (DEX) 
(Oradexon, Organon) (group APD), or 20 mg/kg bw hydrocortisone (HYD) (Solu-Cortef, 
Pharmacia&Upjohn) (group APH) or 5 mg/kg bw RU (Roussel-Uclaf, France) (group APRU) 
subcutaneously just prior to the induction of AP. RU was incorporated into multilamellar 
phospholipid liposomes prepared from phosphatidylcholine (Sigma Chem., U.S.A.) and 
cholesterol (Sigma Chem., U.S.A.) according to the method described earlier. In sham-
operated groups 5-8, the animals underwent the same surgical interventions, but sterile saline 
was used as infusate into the pancreas (group Sham) or the animals received subcutaneously 
(sc.) the same doses of DEX (group ShamDEX), HYD (group ShamHYD), or RU (group 
ShamRU). 
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The animals were randomly assigned into one or other of three experimental series. In series 1 
(n = 48), the mortality of AP was investigated. The animals were observed for 24 h, and the 
number of survivors was recorded. Series 2 (n = 178) was used for serum cytokine, amylase 
and pancreatic weight/body weight (pw/bw) determinations. Blood samples were obtained 2, 
4, 8 and 24 h after AP induction. Tissue biopsies were taken for ATP and MPO measurements 
of the liver and lungs, and for histology of the pancreas, 24 h after AP induction. In the sham-
operated series 3 (n = 60) blood samples were taken at 4 and 8 h, and tissue biopsies were 
taken at 24 h after surgery. 
 
2.1.2. Study II 
In the second study, the rats were randomly allocated into one or other of three groups. In the 
group AP, AP was induced by the intraperitoneal (ip.) administration of L-arginine (L-Arg) (2 
x 250 mg/100 g bw). In groups APMP and APRU, the animals were given 30 mg/kg MP, 
(Organon) or 5 mg/kg RU (Roussel-Uclaf, France), respectively. The agonist and antagonist 
were administered sc. just prior to the induction of AP. In the control group (group C), the 
animals were given a saline injection sc. and were euthanized at 0, 8, 12 or 24 h without 
undergoing any other procedure. Each group contained at least 6 animals. 
 
2.2. Surgical preparation 
2.2.1. Experimental acute pancreatitis 
In the first study, the surgical procedures were performed under Na-pentobarbital (40 mg/kg 
ip.) anesthesia. The abdomen was shaved, prepped, and draped in sterile fashion, and after a 
midline laparotomy, the pancreatic duct was cannulated at its entry into the duodenum, using 
a PE 50 catheter, fixed and connected to a pressure-controlled precision pump (IVAC, San 
Diego, CA). Prior to infusion, the common bile duct was occluded with a microvascular metal 
aneurysm clamp at the hilus of the liver, where the infusate entered the pancreas. 400 µl 3% 
Na-taurocholate (Sigma, U.S.A.) was perfused under standard parameters (pressure and 
volume) for 30 s. After the intraductal infusion, the bile duct clamp was removed, the cannula 
was withdrawn, and the abdomen was closed in two layers. 
Int the second series, the experimental AP was induced by the ip. administration of L-Arg 
(2x250 mg/100 g bw). 
 
2.2.2. Collection and analysis of plasma samples 
 9 
Rats were laparotomized and sacrificed by abdominal aorta exsanguination under 
pentobarbital anesthesia 2, 4, 8, or 24 h in study I or 0, 8, 12 and 24 h following AP induction 
in study II. Blood samples were collected in heparinized tubes by exsanguinating the animals 
through the abdominal aorta. The blood was centrifuged at 3000 g for 10 min immediately 
after collection, and the plasma was separated through the use of sterile pipets and stored at -
70 ºC until it was assayed. 
 
2.3. Measurements 
2.3.1. Survival analysis 
In the first experiments, we investigated the survival rates 24 h after the induction of 
experimental AP by taurocholic acid. In the second series, survival analysis was not 
performed because in this dose the L-Arg-induced AP did not result in mortality.  
 
2.3.2. Pancreatic weight / body weight (pw/bw) ratio determination 
The pancreas was removed immediately after the blood collection, trimmed free of fat and 
lymph nodes, and weighed. The pw/bw ratio (mg/g) was calculated for each animal, to 
estimate the level of pancreatic edema.  
 
2.3.3. Plasma amylase activity 
Plasma amylase levels were measured by the amylase test of Phadebas et al. and are reported 
in standard units 
 
2.3.4. Cytokine assays 
2.3.4.1. Plasma IL-6 activity 
IL-6 was bioassayed by using the murine hybridoma cell line B9, the proliferation of which is 
IL-6-dependent.  
 
2.3.4.2. Macrophage migration inhibitory factor activity 
Plasma MIF concentration was measured with a sandwich enzyme immunoassay kit (Chem. 
Int. Inc., USA) according to the manufacturer’s instructions.  
 
2.3.5. Assay of inflammatory mediators in pancreatic tissue 
2.3.5.1. Nuclear transcription factor kappa B analysis 
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The proinflammatory cytokines TNF and IL-1-beta are known to activate NF-κB. This fact 
was made use of to estimate the production of inflammatory mediators in tissue homogenates 
(where the reliability of other assays is limited). 
Tissue biopsies were taken at 0, 8, 12 and 24 h following AP induction, trimmed free of fat 
and lymph nodes, weighed and frozen at -70 ºC until use. After mincing and ultrasonic 
homogenization, the debris was pelleted by low-speed centrifugation and the supernatant was 
used for the assay. 
 
2.3.6. Reporter cell lines 
Mouse L929 cells (5 x 105 cells on a 60-mm plate) were transformed with pNF-κB-luc4 and 
pSV-2/neo plasmids (coding for firefly luciferase under the control of 5 NF-κB-responsive 
elements and the neor gene controlled by the SV40 enhancer/promoter, respectively), using 
the DMIRIE-C cationic lipid transfection agent (GIBCO BRL). Selection on Geneticin G418 
(400 mg/l) started 48 h later, the medium being refreshed twice weekly. Clones were isolated 
and tested for the intensity of their TNF-elicited NF-κB induction (50-100 U/ml recombinant 
TNF, 6-10 h of induction) and the most responsive clones were used in subsequent 
experiments. 
RAW 264.7 cells (5 x 105/60-mm plate) subcultured on the previous day were transformed 
overnight with the above plasmids complexed with polyethylene-imine (jetPEI, Qbiogen, 
Illkirch, France).  
 
2.3.6.1. Media 
Both cell types were grown in MIX MEM (a 1:1 mixture of DMEM, Sigma Cat. no. D-7777 
and F-12 HAM, Sigma Cat. No. N-4388) plus 10% fetal calf serum (FCS) (Sigma, Cat. no. F-
4135). Transformation was carried out in OPTI MEM (GIBCO BRL).  
 
2.3.6.2. Luciferase assay 
One-day-old cultures (of both L929 and RAW 264.7 cells), grown on luminoplates (Corning-
Costar Cat. no 3903) at 3 x 104 cells/well in MIX MEM 10% FCS, were exposed to tissue 
samples, TNF or LPS, respectively (in 100 µl of the above medium per well).  
 
2.3.7. Analysis of liver and lung tissue samples 
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Simultaneously with the pancreas-removing processes, tissue samples were obtained from the 
liver and lungs and immediately processed, snap-frozen in liquid nitrogen for MPO and ATP 
assays, and stored at -37 ºC. 
 
2.3.7.1. Myeloperoxidase activity 
The tissue MPO activity, as a marker of tissue leukocyte infiltration, was measured in liver 
and lung biopsies by the method of Kuebler et al. 
  
2.3.7.2. ATP measurement 
Samples were taken from the liver and lungs with a Wollenberg forceps cooled in liquid 
nitrogen, and the tissue was stored at -70 oC. The ATP concentration was measured 
spectrophotometrically according to Lamprecht et al. 
  
2.3.8. Histology 
Tissue biopsies were taken for histology of the pancreas, lungs and liver 24 h after AP 
induction. The severity of the AP was determined by gross scoring of the macroscopic 
parameters of the pancreas pathology, including pancreatic edema, hemorrhage and fat 
necrosis.  
The systemic damage involved in the pancreatitis was scored for 24 h in different target 
organs such as the liver and lungs.  
 
2.3.9. Light microscopy 
The hematoxylin and eosin stained slides were coded and read for the histological markers of 
tissue injury by one independent observer in a blinded fashion. The different special 
histological signs were graded semiquantitively in 8-10 consecutive high-power fields (x400). 
The score for each graded parameter was averaged and the total tissue damage was calculated 
by summing the averages. 
 
2.3.10. Data analysis and statistical comparisons  
Survival data were analyzed for statistical significance by the Fisher exact test. In the case of 
biochemical measurements for statistical analysis, a nonparametric method was used. Time-
dependent differences from the baseline were assessed by Dunn’s method. Differences 
between groups were analyzed with Kruskal-Wallis one-way analysis of variance on ranks, 
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followed by Dunn's method for pairwise multiple comparison. P values <0.05 were 
considered statistically significant. Results are expressed as means ± S.E.M. 
 
3. RESULTS 
 
3.1. Study I 
3.1.1. Survival analysis 
In the non-treated AP group, the experimentally induced AP resulted in a 33% (4/12) survival 
rate, with a median survival of 10 h after an observation period of 24 h. However, the 
glucocorticoid agonists decreased the lethal effect of AP: in the groups APD and APH, the 
24-h survival rates were 58% (7/12) and 75% (9/12), with a median survival of 17 and 19 h, 
respectively. In the group APRU, the resistance of the animals against AP was significantly 
decreased as compared with the groups APD and APH: the survival rate was only 17% (2/12). 
In the Sham group, the mortality was 0. 
 
3.1.2. Pw/bw ratio 
Pw/bw was significantly elevated in the group AP vs the normal condition (p<0.05). No 
difference between the groups AP and APRU was found at any time point. In the groups APD 
and APH, pw/bw was significantly diminished (p<0.05) vs the group AP. In the SHAM 
groups, the pw/bw ratio did not change significantly. 
 
3.1.3. Plasma amylase activity 
In the group AP, the amylase activity was significantly elevated at 2 h (13000 U/l ± 3000 U/l) 
and remained higher at 4, 8 and 24 h vs the basal level (p<0.05). In the glucocorticoid agonist-
treated groups (groups APD and APH), the plasma amylase levels were significantly 
decreased as compared with the group AP at 2, 4 and 8 h (p<0.05). No significant alteration in 
amylase activity was found in the group APRU vs the group AP. In the SHAM groups, the 
glucocorticoid agonists and antagonists did not alter the basal amylase level significantly at 
any time point as compared with saline treatment. 
 
3.1.4. Plasma IL-6 activity 
In the group AP, the IL-6 level gradually increased, reaching its peak at 8 h (13500 U/l ± 
3000 U/l). In the group APRU, the IL-6 value was significantly elevated (16000 U/l ± 3800 
U/l) at 2h following AP induction as compared with the other groups (p<0.05). At 4, 8 and 24 
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h, its levels did not differ from those for the group AP. In the groups APD and APH, the IL-6 
activity was significantly diminished (p<0.05) as compared with the group AP at 4, 8 and 24 
h. The circulating IL-6 level did not change significantly in the SHAM group. 
 
3.1.5. Liver and lung MPO activity 
AP significantly elevated the leukocyte accumulation both in the liver and in the lungs 
(p<0.05) as compared with the SHAM group. RU treatment did not influence the MPO 
activities of the organs as compared with the group AP. DEX and HYD, however, 
significantly (p<0.05) attenuated the leukocyte accumulation in the liver 24 h following AP 
induction as compared with the AP group. In the glucocorticoid agonist and antagonist-treated 
SHAM groups, the MPO activity did not change significantly as compared with saline 
treatment. 
 
3.1.6. Liver and lung ATP activity 
AP alone resulted in significantly decreased ATP levels in both the liver and the lung tissue at 
the end of the observation period as compared with the Sham group (p<0.05). In the group 
APRU, the liver and lung ATP levels were similarly significantly (p<0.05) decreased vs the 
group Sham, but did not differ from that for the group AP. In the groups, APD and APH, the 
liver ATP levels were significantly (p<0.05) elevated as compared with the group AP. No 
significant differences were detected between the groups AP and APRU vs the groups APD 
and APH in the lung tissue ATP level. In the Sham groups (Sham, ShamDEX, ShamHYD and 
ShamRU), the ATP contents of the liver and lung tissue did not change significantly as 
compared with saline treatment. 
 
3.1.7. Gross pathology 
The scores were significantly improved in the groups APH and APD as compared with the 
group AP (p<0.05). In the AP and the groups APRU, macroscopic analysis revealed more 
severe pathological parameters than in the groups APH and APD. 
 
3.1.8. Histology 
Although the gross pathological and the microscopic findings following hematoxylin-eosin 
staining demonstrated appreciable histological changes in the pancreas, liver and lungs in the 
different groups, the differences in the investigated organs were not statistically significant. 
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3.2. Study II 
3.2.1. Pw/bw ratio 
The administration of L-Arg significantly increased the pw/bw ratio vs that in the group C 
(p<0.05). Glucocorticoid pretreatment tended to decrease the pw/bw ratio in the AP group, 
but this difference was not statistically significant. 
 
3.2.2. Plasma amylase activity 
In the AP and APRU groups , the amylase activities were significantly elevated at 12 h and 
remained higher at 24 h vs the basal level (p<0.05). In the glucocorticoid agonist-treated 
group (group APMP), the plasma amylase level was significantly decreased as compared with 
the groups AP and APRU at 12 and 24 h (p<0.05). No significant alteration in amylase 
activity was found in the group APRU vs the group AP. 
 
3.2.3. Plasma IL-6 activity 
In the group AP, the IL-6 level gradually increased, reaching its peak (1000 ± 200 U/l) at 8 h. 
In the group APRU, the IL-6 level was significantly elevated (750 ± 100 U/l) at 8 h and 12 h 
following AP induction as compared with the group APMP (p<0.05). In the group APMP, the 
IL-6 activity was significantly diminished (p<0.05) as compared with the group AP at 8 h. 
The circulating IL-6 level did not differ significantly between the groups AP and APM from 
12 h up to the end of the observation period. 
 
3.2.4. Plasma MIF level 
AP induced increases in the baseline plasma MIF level at 8, 12 and 24 h. MP did not exert a 
significant effect on the plasma MIF level changes. RU treatment resulted in significantly 
higher MIF production at 8 and 12 h following L-Arg injection as compared with the groups 
APMP and AP. 
 
3.2.5. Proinflammatory cytokines in the pancreas 
In the early phase of AP, the level of pancreatic NF-κB activity changed in parallel in the MP- 
and RU-treated groups, and the difference between these groups was not statistically 
significant at 8 h following L-Arg injection. 
MP treatment significantly decreased the level of NF-κB activity as compared with the RU-
treated animals at 12 h following AP induction. Similarly, in the group APMP the pancreatic 
NF-κB concentration was significantly decreased as compared with the group AP at 24 h. RU 
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treatment resulted in a significantly higher level of pancreatic NF-κB activity at 12 h vs the 
groups AP and APMP. AP alone led to a significantly higher NF-κB activity as compared 
with the group C at 24 h. 
 
3.2.6. Gross pathology 
The administration of 2x250 mg/100 g bw L-Arg induced mild necrotizing AP.  
The scores were significantly better in the group APMP as compared with the group AP 
(p<0.05). In the group APRU, the macroscopic analysis revealed more severe pathological 
parameters than in the group APMP. 
 
3.2.7. Histology 
However, at the end of the observation period, the extents of tissue damage in the pancreas 
and lungs were significantly less in the group APMP than in the groups AP and APRU. 
 
4. DISCUSSION 
 
AP is an inflammatory disorder of the pancreas with local and systemic manifestations, is a 
significant health problem. In spite of the improvements that have been achieved in intensive 
care and in surgical therapy, the mortality rate for necrotizing AP remains high. Activation of 
the inflammatory cascade, including different cytokines, results in microcirculatory 
disturbances and multiple organ failure. Among the most important aspects of the in vivo 
investigation of AP is the use of a relevant animal model which is able to mimic the clinical 
situation. Different experimental models of AP have been developed in order to seek an 
understanding of its pathophysiology, histological features and degree of severity, and the 
failure of distant organ systems. 
In order to demonstrate the effects of glucocorticoids on AP we chose a severe model of AP. 
In study I, we applied the Na-taurocholate-induced AP model. This is an accepted and 
reproducible model of experimental AP, which produces the characteristic morphological and 
physiological changes of severe necrotizing type AP.  
The biochemical and morphological data proved that Na-taurocholate administration did 
result in a severe necrotizing type of AP. In study II, we also chose a severe pancreatitis 
model. The L-Arg-induced noninvasive model is highly reproducible and standardizable, and 
produces selective, dose-dependent AP. With a low dose of L-Arg, the induced pancreatitis is 
not so severe and does not result in mortality. Increases in tissue corticosteroid levels during 
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an acute illness are important protective responses. There is now preliminary evidence to 
support the use of supplementary corticosteroids in patients with established septic shock, and 
especially those who display signs of functional hypoadrenalism. 
However, the beneficial effects of exogenously administered corticosteroid hormones in 
experimentally induced AP are a matter of dispute. It is well known that the pituitary-adrenal 
axis, including glucocorticoids, plays a pivotal role in the mutual control mechanisms and 
communication between the neuro-endocrine and immune systems. During experimental AP, 
the extent of secretion of endogenous corticosterone is increased. Adrenalectomy is known to 
produce more severe AP and to elevate the serum IL-8 level. 
Our results clearly demonstrate that glucocorticoid hormones attenuate the local and systemic 
effects of AP and prolong the survival of rats. 
The injection of HYD during the development of AP was observed by Pescador et al. and by 
De Dios et al. to be harmful. In contrast, the protective effects of corticosteroids in AP have 
been reported by several authors. Furthermore, glucocorticoids have been found to attenuate 
the pancreas damage by protecting acinar cells during cerulein-induced AP, whereas the 
opposite was reported by Manso et al. in AP induced with a choline-deficient, ethionine-
supplemented diet. 
Our observations are in line with these findings, since the glucocorticoid agonists HYD, DEX 
and MP moderated the serum amylase and IL-6 activities and local inflammatory reactions. In 
contrast, the glucocorticoid antagonist RU amplified the inflammatory processes and resulted 
in an earlier IL-6 response to AP. 
It has been established that the steroid receptor antagonist RU enhances the synthesis of TNF-
α and sensitizes animals to the cytotoxic action of TNF-α. RU acts at the receptor level, and 
thus the increased TNF-α production seems to be mediated via the glucocorticoid receptors. 
As the most powerful inducer of IL-6 production is TNF-α, and glucocorticoids inhibit IL-6 
synthesis directly, the earlier significant IL–6 production in the RU group can be explained.  
 One of the crucial points of these studies is the timing of steroid treatment during AP. 
Thcolakov et al. and Gloor et al. observed that treatment with a single prophylactic, low dose 
of exogenous steroid resulted in a decrease in the severity of AP. Repeated long-term HYD 
pretreatment has been demonstrated to worsen the inflammatory process in AP. Another 
controversial point is the dose of steroid treatment. High-dose corticosteroid treatment (mg/kg 
bw) increases the mortality rate, possibly due to secondary infection. On the other hand, low-
dose (10 mg/kg bw) steroid treatment results in a more effective inhibition of inflammatory 
mediators (IL-8, TNF-α and arachidonic metabolisms), a better survival and a lower rate of 
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side-effects. The opposite was reported by Gloor et al.: they administered 10 mg/kg bw HYD 
10 min following the induction of cerulein-induced AP, but this did not result in any 
protective effect. These controversial results might be explained by the differences in timing, 
the dose of glucocorticoid treatment and the type of experimental AP. We used twice as high 
a dose of HYD (20 mg/kg bw), and a much stronger glucocorticoid analog, DEX, in a dose of 
4 mg/kg bw. In spite of the differences in biological half-life, the two steroid analogs 
achieved the same result. These findings suggest that even the glucocorticoid compound with 
weaker anti-inflammatory potency (i.e. HYD) could adequately attenuate the inflammatory 
mediator response in this setting. 
Recent studies have led to the rediscovery of a pituitary mediator that appears to act as the 
counter-regulatory hormone for corticoid action within the immune system. The protein 
historically known as MIF was identified more than 40 years ago as a product of antigen-
sensitized lymphocytes that could inhibit the random movement or migration of cultured 
mononuclear cells in vitro. 
Low concentrations of glucocorticoids directly induce MIF release from macrophages and T 
cells. This finding was initially surprising because it was generally considered that 
glucocorticoids inhibit the release of proinflammatory mediators. The glucocorticoid-induced 
secretion of MIF is tightly and dose-dependently regulated. At high anti-inflammatory 
glucocorticoid concentrations (>10-8 M), the secretion of MIF is known to be completely shut 
off. 
It is of importance that MIF circulates normally in the blood. The basal MIF levels have been 
estimated by ELISA techniques to range from 2 to 4 ng/ml amounts that demonstrate 
glucocorticoid counter-regulatory activity in vitro. These data suggest that the physiological 
state of the glucocorticoid-MIF system is one of an active balance between pro- and anti-
inflammatory mechanisms. 
MIF production seems to be upregulated in other cases of pancreatitis too, and its presence 
can be regarded as an early marker of pancreatic necrosis in AP.  
We demonstrated that the induction of AP by the injection of L-Arg resulted in a marked 
increase in the MIF concentration in the plasma. There was a continuous tendency for the 
administration of high doses of MP to elevate the plasma MIF level, but this effect was not 
statistically significant. Our finding had previously been suggested by recent studies on the 
effects of glucocorticoids on MIF production in different acute inflammatory processes. 
Nagasaki et al. reported that MP did not increase, but rather tended to decrease the serum MIF 
level. Similarly, in experimental rat models Bruhn et al. observed that the administration of 
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DEX did not enhance MIF production in sepsis. Our results are in accord with the findings of 
these authors, who concluded that exogenously administered glucocorticoid treatment 
downregulated the level of cell-associated MIF and MIF release by various activators. The 
fact that MP did not further increase the production of MIF in our experiments suggested that 
the degree of glucocorticoid-induced MIF production was already maximal in the AP animals 
because of the high level of endogenous glucocorticoids. On the other hand, one of the most 
interesting observations in the second phase of the study was that RU treatment resulted in 
significant elevations of the plasma level of MIF 8 and 12 h after AP induction. However, 
there is no clear-cut explanation for this fact. Very little is known about the regulation of the 
MIF gene; some data suggest that NF-κB is involved. 
Glucocorticoid hormones diminish the production of inflammatory cytokines via the 
inhibition of cytoplasmic transcriptional factors such as NF-κB. The glucocorticoids activate 
glucocorticoid receptors that may then bind to activated NF-κB and activator protein-1, 
preventing binding to κB sites on genes that have a role in inflammatory processes. 
Our important major finding is that MIF counteracts the glucocorticoid-mediated inhibition of 
NF-κB in L-Arg-induced experimental AP in rats. Our results suggest that NF-κB activation 
in L-Arge-induced AP occurs at a later stage as compared with other models. A significant 
NF-κB elevation was detected 1 h after the induction of AP with Na-taurocholate. 
We found that RU treatment led to in significantly higher NF-κB activity 12 h after 
pancreatitis induction, which can be explained in that RU treatment results in significantly 
higher MIF production at this time. It was clear that the short-term pretreatment with a high 
dose of glucocorticoid caused a significant lowering of the NF-κB activity in the later phase 
of AP. 
Many inflammatory components are regulated by NF-κB, including inflammatory cytokines, 
acute-phase proteins, etc. Glucocorticoid hormones are known to diminish the production of 
inflammatory cytokines via the inhibition of cytoplasmic transcriptional factors such as NF-
κB. Glucocorticoids prevent NF-κB activation in part by increasing the expression of nuclear 
factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha (IκBα), which keeps 
NF-κB bound in the cytosol and thereby prevents the gene expression of proinflammatory 
mediators. The mechanism for the counter-regulatory action of MIF involves the prevention 
of glucocorticoid-induced increases in cytosolic IκBα. As a consequence, NF-κB can 
translocate to the nucleus and activate transcription, even in the presence of normal 
physiological concentrations of HYD. MIF could activate an intracellular pathway, leading to 
IκBα kinase activation and consequences of IκBα degradation, in this way overriding the 
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glucocorticoid-induced inhibition of NF-κB activation. Moreover, glucocorticoid increases 
the expression of IκBα, preventing NF-κB translocation to the nucleus and the activation of 
transcription. 
We demonstrated that experimental animals respond to AP with a significantly higher degree 
of tissue leukocyte infiltration, as evidenced by the increased MPO activity in the liver and 
lungs. It is noteworthy to note that in experimental AP the glucocorticoid agonists attenuated 
the MPO activity. This finding underlines the importance of the action of glucocorticoid in 
the control of inflammatory mediator-induced remote organ damage.  
Previous nuclear magnetic resonance studies have revealed the depletion of high-energy 
phosphates in pancreatic cells in AP, which seems to occur as a result of pancreatic cell death. 
Halangk et al. reported a correlation between the degree of depletion of high-energy 
phosphates and the severity of AP. In this process, the main source of the enhanced 
permeability of the mitochondrial inner membrane is the inhibition of complex I of the 
respiratory chain. The hepatocellular dysfunction and ATP depletion in AP are also well 
known, but little attention has been paid to the relationship of steroid treatment and the high-
energy phosphate level in inflammatory processes of the pancreas. In our study in animals 
with AP, a significant ATP depletion was demonstrated in remote organs too. The observation 
that ATP depletion develops in the lungs provides a possible explanation for the pulmonary 
dysfunction seen in AP. It is also possible that other systemic complications, such as a 
decreased myocardial contractility or renal failure, are indirectly related to the mitochondrial 
dysfunction and ATP depletion caused by circulating cytokines and other toxic components. 
Therefore, our results may suggest a novel explanation for the multiple organ dysfunction and 
increased morbidity in AP. On the other hand, low-dose steroid treatment was effective in our 
study, glucocorticoid agonists significantly elevating the liver ATP content in experimental 
AP. 
In our series in the Na-taurocholate-induced AP model, the histological changes in target 
organs were more characteristic than in the L-Arg-induced series. We proved the protective 
effect of glucocorticoid analog treatment on tissue damage. Moreover, at the end of the 
observation period, the extents of tissue damage in the pancreas and lungs were significantly 
less in the glucocorticoid-treated (APMP) groups than in AP and after Ru treatment. 
In conclusion, our study highlights the fact that glucocorticoid hormones play an important 
role in maintaining the resistance of the animals against the lethal effects of experimentally 
induced AP. Furthermore, the exogenously administered glucocorticoid agonists greatly 
moderate the local and systemic inflammatory consequences of experimental AP. 
 20 
 
5. SUMMARY AND NEW FINDINGS 
 
The histological and biochemical findings proved that both Na-taurocholate and L-Arg 
induced a severe type of AP. These two reproducible and standardized in vivo experimental 
models provide useful protocols which furnished valuable information on the functional, 
morphological and biochemical changes during the initiation phase of AP, and on the 
pathophysiological and morphological consequences of AP in response to different 
treatments. 
Our results clearly demonstrated that glucocorticoids critically mitigate the progression of the 
inflammatory reaction during the early phase of experimental AP. 
Exogenously administered short-term pretreatment with high-dose glucocorticoid hormones 
attenuated the local and systemic effects of AP, decreased the serum amylase and IL-6 
activities and local inflammatory reaction, and prolonged the survival of the animals. 
Our study has proved that experimental animals respond to AP with a significantly higher 
degree of tissue leukocyte infiltration, as evidenced by the increased MPO activity in the liver 
and lungs. It must be noted that in experimental AP the glucocorticoid agonists attenuated the 
MPO activity.  
Our study demonstrated a significant ATP depletion in the liver and the lungs of animals with 
AP. The observation of an ATP depletion in the lungs provides a possible explanation for the 
pulmonary dysfunction seen in AP. Steroid treatment was effective in our study, 
glucocorticoid agonists significantly elevating the liver ATP content in experimental AP. 
Furthermore, inhibition of the endogenous corticosteroid action by RU treatment also resulted 
in a pronounced ATP depletion in remote organs, this process being inhibited by 
glucocorticoid agonists. 
The induction of AP by the injection of L-Arg led to a marked increase in the MIF 
concentration in the plasma. There was a continuous tendency for the administration of high 
doses of MP to enhance the plasma MIF level, but this effect was not statistically significant. 
On the other hand, treatment with the antiglucocorticoid RU gave rise to significant elevations 
of the plasma level of MIF after AP induction. 
The other important major finding was that MIF counteracted the glucocorticoid-mediated 
inhibition of NF-κB in L-Arg-induced experimental AP in rats. Our results suggested that NF-
κB activation in L-Arg-induced AP occurs at a later stage as compared with other models. 
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We clearly demonstrated that short-term pretreatment with a glucocorticoid agonist resulted 
in a significant reduction of NF-κB activity in the later phase of AP. 
In conclusion, our study clearly revealed that glucocorticoid agonist treatment promotes the 
resistance of animals against the lethal effects, and provides considerable protection against 
the systemic toxicity of inflammatory cytokines of experimentally induced AP.  
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